Cardiovascular Outcomes With Sodium-Glucose Cotransporter 2 Inhibitors in Ethnically Diverse Patients With Heart Failure.

BACKGROUND

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been shown to decrease heart failure hospitalizations (HFHs) and cardiovascular (CV) death; however, Hispanic/Latino patients and methamphetamine (MA) users have been under-represented.

PROJECT RATIONALE: The purpose of this retrospective study was to assess CV outcomes in the Central Valley region of California within 12 months of starting a SGLT2i.

PROJECT SUMMARY: Overall, 413 patients were included, with non-White patients and MA users accounting for 72% and 27% of the population, respectively. The composite CV outcome occurred in 86 of 413 patients (20.8%), 22% of Whites and 19%-27% of non-Whites. Significantly reduced HFH rates were observed in the overall population and subgroups after 1 year of starting SGLT2i. Reduced left ventricular ejection fraction, prior HFH, and MA use predicted CV outcomes, though the retrospective nature of this analysis limits causal inference.

TAKE-HOME MESSAGE: MA use, prior HFH, and reduced left ventricular ejection fraction predicted CV outcomes, irrespective of ethnicity.